EGFR and neoplasm: Anti-EGFR therapies consequently have been in the focus of attention: antibodies, tyrosine kinase inhibitors (TKIs), or vaccines were tested in GBM patients, but largely remained unsuccessful,8–10 due to limited drug delivery to the brain, tumor heterogeneity, and acquired resistance.